Targeted Treatment Of Anerobic Cancer

Abstract

The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.

We claim: 
     
         1 . A pharmaceutical composition comprising an effective amount of a lactate transporter inhibitor, loop diuretic, and an angiogenesis inhibitor, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate. 
     
     
         2 . The composition according to  claim 1 , wherein said angiogenesis inhibitor is bevacizumab. 
     
     
         3 . The composition according to  claim 1 , wherein said loop diuretic is bumetanide. 
     
     
         4 . The composition according to  claim 1 , wherein said lactate transporter inhibitor is packaged within liposomes. 
     
     
         5 . The composition according to  claim 1  formulated for oral administration. 
     
     
         6 . The composition according to  claim 1  formulated for parenteral administration. 
     
     
         7 . The composition according to  claim 6  formulated for intravenous administration. 
     
     
         8 . A pharmaceutical composition comprising an effective amount of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, and an angiogenesis inhibitor, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate. 
     
     
         9 . The composition according to  claim 8 , wherein said angiogenesis inhibitor is bevacizumab. 
     
     
         10 . The composition according to  claim 8 , wherein said carbonic anhydrase inhibitor is acetazolamide. 
     
     
         11 . The composition according to  claim 8 , wherein said lactate transporter inhibitor, carbonic anhydrase inhibitor, and said angiogenesis inhibitor are in a mixture. 
     
     
         12 . The composition according to  claim 8  formulated for oral administration. 
     
     
         13 . The composition according to  claim 8  formulated for parenteral administration. 
     
     
         14 . The composition according to  claim 8  formulated for intravenous administration. 
     
     
         15 . The composition according to  claim 8 , wherein said lactate transporter inhibitor is packaged within liposomes. 
     
     
         16 . A pharmaceutical composition comprising an effective amount of a lactate transporter inhibitor, a NKCC inhibitor, and an angiogenesis inhibitor, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate. 
     
     
         17 . The composition according to  claim 16 , wherein said lactate transporter inhibitor, a NKCC inhibitor, and said angiogenesis inhibitor are in a mixture. 
     
     
         18 . The composition according to  claim 16  formulated for oral administration. 
     
     
         19 . The composition according to  claim 16  formulated for intravenous administration. 
     
     
         20 . The composition according to  claim 16 , wherein said composition is packaged within liposomes.